Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 5R01AI100059-02 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institutes of Health (NIH) | NIH |
| National Institute of Allergy and Infectious Diseases (NIAID) | NIH |
| Centers for Disease Control and Prevention | FED |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Despite increased HIV (Human Immunodeficiency Virus) infection testing in Africa, many patients never enroll in subsequent HIV care after testing or remain in care after an initial enrollment. This study's aim is to improve linkage to HIV care and retention in HIV care through the use of feasible, evidence-based, and practical interventions. The study takes place in Swaziland, the country with the highest HIV prevalence (24%) in sub-Saharan Africa. The study will randomize groups of HIV testing sites and affiliated clinics to either standard of care or a combined intervention strategy (CIS) which consists of point-of care CD4 (cluster differentiation 4 (CD4)) testing at time of HIV testing, fast-track HIV medications for those who are eligible for treatment,mobile phone appointment reminders, care bags filled with health prevention materials, and financial incentives. The study outcomes are linkage to and retention in care as well as cost effectiveness, feasibility of interventions, and patient acceptability of interventions.
Linkage of patients from HIV testing to HIV care programs and their retention once enrolled in care are essential to HIV program effectiveness in terms of prevention of HIV;related morbidity and mortality and prevention of HIV transmission. Linkage and retention rates in HIV programs in sub-Saharan Africa (SSA) are suboptimal, with less than half of patients who test positive successfully linking and remaining in care at 1 year. This study is a two-arm cluster site;randomized trial to compare the effectiveness of a novel combination package of evidence;based interventions, the combination intervention strategy (CIS), compared to standard of care (SOC) on linkage and retention of HIV;positive patients from point of testing to retention in care. CIS will include 1) point of care CD4+ count assays at HIV testing sites; 2) accelerated antiretroviral therapy (ART) initiation for eligible patients; 3) provision of a basic care and prevention package (BCPP); 4) short message service (SMS) reminders for clinic appointments; and 5) financial incentives for linkage and retention. The primary aim is to evaluate the effectiveness of CIS as compared to SOC on the combined outcome of rapid linkage to HIV care within 1 month and retention in care at 12 months among adults testing positive for HIV. Secondary aims include evaluation of the effectiveness of CIS compared to SOC on each of linkage to HIV; retention in care; time to ART initiation; HIV disease progression and mortality; patient acceptability; association between baseline characteristics and outcomes, and comparison of cost effectiveness.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Standard of Care | No Intervention | Participants will be managed per standard of care following prevailing Swaziland Ministry of Health guidelines. | |
| Combined Intervention Strategy | Experimental | Point-of-care (POC) CD4+ (cluster of differentiation 4) Count Accelerated ART initiation for ART eligible participants Basic care and prevention package Cellular Appointment Reminders and Follow-Up Financial Incentives |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| POC (point-of-care) CD4+ (cluster of differentiation 4) Count | Procedure | Each HIV testing and counseling (HTC) site will be equipped with POC CD4+ testing using PIMAâ„¢ Analyser (Inverness), test strips, and reagents. Study staff will obtain 25 microliters of blood via finger prick and process the POC (point-of-care) CD4+ (cluster of differentiation 4) Count' test immediately following the baseline interview. Test results will be recorded on study forms including a referral form that has multiple copies, one copy to be given to the participant, the second sent to the affiliated HIV (Human immunodeficiency virus)care clinic in the study unit, and the third kept by study staff in a locked cabinet with other confidential material. All participants, regardless of the CD4+ result, will be encouraged to enroll in HIV care as soon as they can. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in proportion of participants who both link to care at assigned study unit within 1 month and are retained in care at the designated study unit 12 months after HIV (Human Immunodeficiency Virus) diagnosis | Combined outcome of linkage to HIV care within 1 month after testing HIV positive and retention in care 12 months after testing. Participants are considered to achieve this outcome if they successfully link to the HIV clinic at their study unit (SU) within 1 month of testing HIV positive and are retained in care at the HIV clinic at their SU 12 months after testing HIV positive, as measured from medical records. | one month after enrollment, 12 months after enrollment |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of participants successfully linked to care at designated study unit within 1 month of HIV diagnosis | Linkage to care within 1 month of HIV testing (at any clinic within the assigned study unit). | 12 months after enrollment |
| Proportion of participants retained in care at designated study unit 12 months after HIV diagnosis. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in adjusted risk ratio comparing proportion of participants who both link to care at assigned study unit within one month and are retained in care at designated study unit twelve months after HIV diagnosis | Adjusted risk ratio comparing proportion of participants who both link to care at assigned study unit within one month and are retained in care at designated study unit twelve months after HIV diagnosis, by strata of age, sex, and other socio-demographic variables |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Wafaa El-Sadr, MD MPH | Columbia University | Principal Investigator |
| Charles Azih, MD MPH | Swaziland MOH | Study Director |
| Scott Braithwaite, MD MSc | New York University | Study Director |
| Batya Elul, PhD MD | Columbia University | Study Director |
| Peter Ehrenkranz, MD MPH | Centers for Disease Control and Prevention | Study Director |
| Matthew Lamb, PhD MPH | Columbia University | Study Director |
| Margaret McNairy, MD MSc | Columbia University | Study Director |
| Phumzile Mndzebele | Swaziland MOH | Study Director |
| Ruben Sahabao, MD | ICAP Swaziland | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Bhalekane Clinic | Swaziland | Eswatini | ||||
| Dvokolwako |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 29112963 | Derived | McNairy ML, Lamb MR, Gachuhi AB, Nuwagaba-Biribonwoha H, Burke S, Mazibuko S, Okello V, Ehrenkranz P, Sahabo R, El-Sadr WM. Effectiveness of a combination strategy for linkage and retention in adult HIV care in Swaziland: The Link4Health cluster randomized trial. PLoS Med. 2017 Nov 7;14(11):e1002420. doi: 10.1371/journal.pmed.1002420. eCollection 2017 Nov. | |
| 26189154 | Derived | McNairy ML, Gachuhi AB, Lamb MR, Nuwagaba-Biribonwoha H, Burke S, Ehrenkranz P, Mazibuko S, Sahabo R, Philip NM, Okello V, El-Sadr WM. The Link4Health study to evaluate the effectiveness of a combination intervention strategy for linkage to and retention in HIV care in Swaziland: protocol for a cluster randomized trial. Implement Sci. 2015 Jul 19;10:101. doi: 10.1186/s13012-015-0291-4. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| New York University |
| OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| Accelerated ART (antiretroviral therapy) Initiation | Procedure | Accelerated ART initiation for patients with POC CD4+ < 350 cells/uL (micro-liter) within 1 week from testing. 2 counseling sessions (one at time of HTC and other at first HIV clinic visit), and collection of blood for other baseline lab tests, but initiation prior to return of results for patients who do not meet criteria for waiting |
|
| Basic Care and Prevention Package | Behavioral | Basic care and prevention package (BCPP) provided approximately every three months that includes: condoms; soap, pill box and pictorial education about use of materials and HIV, such as family testing tools and information. Information on BCPP contents and review the educational materials will be provided. An example of educational materials is a family-testing tool to encourage the participant to have all family members tested for HIV. All BCPP items will be replenished every 3 months for all participants, regardless of ART status, beginning at linkage to HIV care. |
|
|
| Cellular Appointment Reminders and Follow-Up | Behavioral | SMS (short messaging service) appointment reminders for follow-up appointments. Telephone call within 7 days of missed appointment for all patients. |
|
| Financial Incentive | Other | Participants will receive a series of financial incentives to support linkage into care within 1 month and retention in care at 6 months and 12 months after testing HIV positive. The value of the financial incentive (FI) will be 80 Swaziland Rand, calculated based on the associated financial costs of traveling to clinic. These incentives will be distributed by through mobile airtime. Participants without mobile phones will be given an alternative incentive of equal value, such as a store voucher. |
|
|
Retention in care 12 months after HIV testing, independent of linkage at 1 month (at any clinic within the assigned study unit). |
| 12 months after enrollment |
| Change in proportion of participants successfully linked to care at any HIV care clinic within one month of HIV diagnosis | Proportion of participants successfully linked to care at any HIV care clinic within one month of HIV diagnosis | one month after enrollment, 12 months after enrollment |
| Median time from HIV testing to initial assessment of ART (antiretroviral) eligibility | Time from linkage to ART eligibility assessment | 12-months after enrollment |
| Median time from HIV testing to ART eligibility | Time from HIV testing to ART eligibility | 12 months after enrollment |
| Proportion of participants who consistently engage in care (attend > 75% of scheduled appointments) | Proportion of participants who consistently engage in care, defined as attend > 75% of scheduled appointments | 12-months after enrollment |
| Change in proportion of participants with new World Health Organization (WHO) Stage III/IV event or hospitalization | Proportion of participants with new WHO Stage III/IV event or hospitalization | 1 month after enrollment,12 months after enrollment |
| Median CD4+ (cluster difference 4) count and viral load 12 months after HIV diagnosis | Median CD4+ cell count 12 months after HIV diagnosis, median viral load 12 months after HIV diagnosis | 12 months after testing HIV-positive |
| Change in Mortality rate | Mortality rate 12 months after HIV diagnosis | 1 month after enrollment, 12 months after enrollment |
| Change in proportion of participants reporting interventions were received | Proportion of participants, who are randomized to study units receiving CIS, reporting receipt of each intervention | 1 month after enrollment, 12 months after enrollment |
| Proportion of participants reporting that interventions were highly acceptable | Proportion of participants, who are randomized to study units receiving CIS, reporting that interventions were highly acceptable | 12 months after enrollment |
| at enrollment, one month after enrollment, 12 months after enrollment |
| Swaziland |
| Eswatini |
| Good Shepherd Hospital | Swaziland | Eswatini |
| Hlatikhulu Hospital | Swaziland | Eswatini |
| Horo | Swaziland | Eswatini |
| Kamfishane | Swaziland | Eswatini |
| Lamvelase | Swaziland | Eswatini |
| Luyengo Clinic | Swaziland | Eswatini |
| Mangweni Clinic | Swaziland | Eswatini |
| Mankayane Hospital | Swaziland | Eswatini |
| Mashobneni Clinic | Swaziland | Eswatini |
| Mbabane Government Hospital | Swaziland | Eswatini |
| Mkhuzweni Health Center | Swaziland | Eswatini |
| Motshane | Swaziland | Eswatini |
| Mpolenjeni Clinic | Swaziland | Eswatini |
| Nhlangano Health Center | Swaziland | Eswatini |
| Piggs Peak | Swaziland | Eswatini |
| Raleigh Fitkin Memorial Hospital | Swaziland | Eswatini |
| Siphofaneni Clinc | Swaziland | Eswatini |
| Sithobeloa Rural Health Center | Swaziland | Eswatini |
| ID | Term |
|---|---|
| D000163 | Acquired Immunodeficiency Syndrome |
| ID | Term |
|---|---|
| D015658 | HIV Infections |
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D015229 | Sexually Transmitted Diseases, Viral |
| D012749 | Sexually Transmitted Diseases |
| D016180 | Lentivirus Infections |
| D012192 | Retroviridae Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D012897 | Slow Virus Diseases |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D007153 | Immunologic Deficiency Syndromes |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D019095 | Point-of-Care Systems |
| D011193 | Potassium Iodide |
| ID | Term |
|---|---|
| D006751 | Hospital Information Systems |
| D006739 | Hospital Administration |
| D058016 | Health Facility Administration |
| D009934 | Organization and Administration |
| D006298 | Health Services Administration |
| D008331 | Management Information Systems |
| D010346 | Patient Care Management |
| D007454 | Iodides |
| D017613 | Iodine Compounds |
| D007287 | Inorganic Chemicals |
| D017680 | Potassium Compounds |
Not provided
Not provided